Women’s health devices maker Halt Medical touted a win from Mexican healthcare regulators who granted registration for the Acessa System for treating uterine fibroids.
The Acessa technology represents a major shift in treatment of uterine fibroids, the company has said. Fibroids are the leading global cause of hysterectomy procedures, according to the Centers for Disease Control & Prevention.
The Las Vegas, Nev.-based company’s Acessa system, which is already on the market in the U.S. Canada and Europe, allows physicians to deliver radiofrequency energy to uterine fibroids through a minimally invasive procedure.
In traditional fibroid surgery a physician generally must either cut through healthy tissue to access the tumor or remove the uterus entirely, according to Halt Medical.
"Mexico is the second largest market for medical devices in Latin America," Halt CEO Jeffrey Cohen said in prepared remarks. "We are very excited to have the opportunity to expand our market reach to virtually all of North America."
